Crosstalk between neuroinflammation and amyloidogenesis in Alzheimer’s disease

Alzheimer’s disease (AD) is the main neurodegenerative disorder that affects 35 million people worldwide. In the absence of efficient treatments AD may soon reach epidemic proportions. The search for novel targets and therapeutic strategies is therefore among the most challenging endeavors of modern neuroscience. This implies a comprehensive approach to study AD based on the interplay between three fundamental processes involved in neurodegeneration: neuroinflammation, amyloidogenesis and synaptic dysfunction. We have recently discovered that membrane type matrix metalloproteinases (MT-MMPs) constitute a new class of proteinases at the crossroads of these processes (PDMI: 28119565, 27349644, 26202697, 25278878). Leveraging on in vivo transgenic mouse models and on murin and human neural cell cultures, the global objective of our work is to further investigate the basic mechanisms that underlie the crosstalk between neuroinflammation, amyloidogenesis and synaptic dysfunction under the scope of MT5-MMP and MT1-MMP, and further validate the modulation of these proteinases as a potential therapeutic strategy in AD.
We use a wide range of methodological approaches techniques, including molecular and cell biology, biochemistry, pharmacology, cell and tissue imaging and electrophysiology.

Share the offer on :